Laser Treatment of Basal Cell Carcinoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04936932

Enrollment

Registered

2021-06-23

Start date

2021-11-01

Completion date

2022-08-20

Last updated

2022-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinoma

Keywords

Superficial Basal Cell Carcinoma

Brief summary

Laser treatment of Basal cell carcinoma

Detailed description

The purpose of this pilot study is to examine the treatment of superficial basal cell carcinoma (BCC) with laser technology. The laser modality that we plan to use is the long-pulse Nd:YAG 1064nm laser, which is a non-ablative laser already shown to effectively treat BCC.

Interventions

DEVICE1064 nm long-pulse Nd:YAG laser

BCC lesion will be treated with long-pulse 1064 laser

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Healthy subjects 18 years of age or older 2. Lesion is biopsy-proven superficial BCC \<= 2.0 cm in largest diameter 3. BCC is on trunk or extremities 4. Seeks and is scheduled for treatment of BCC 5. Willing to have photographs taken of the treatment area 6. Ability to understand and the willingness to sign a written informed consent document 7. Agrees to adhere to the treatment and follow-up schedule and post treatment care instructions

Exclusion criteria

1. Subjects with a BCC lesion that requires excision. This would include relatively larger lesions (\>2.0 cm in diameter), high risk lesions as defined by American Academy of Dermatology as recurrent and sclerosing subtype BCC, or metastases. 2. Pregnancy 3. Subjects unable to follow-up for the full 12-months 4. Subjects not willing to have biopsy taken from the treatment area 5. Subjects with herpes simplex virus infection, impetigo or other disqualifying condition as determined by a dermatologist on the treatment area or effecting healing or outcome

Design outcomes

Primary

Measure	Time frame	Description
Complete clearance of BCC	1 year	Histological confirmation of BCC clearance. Biopsy will be taken from the treatment site to confirm complete BCC clearance

Secondary

Measure	Time frame	Description
Cosmetic outcome	1 year	Cosmetic outcome and any adverse effects of the laser treatment will be assessed

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026